PROX1 and cancer: Gastric cancer patients with high PROX1 expression had a cancer-specific 5-year survival of 65.6% (95% CI 52.7–78.5), compared to 37.1% (95% CI 30.2–44.0) for patients with low expression (p = 0.004, log-rank test; HR = 0.52 (95% CI 0.33–0.82), Fig 2B, Table 2).